SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

The sales is pegged at Rs. 15386.60 millions for the September 2025 quarter. The mentioned figure indicates a decline of about -41.63% as against Rs. 26360.99 millions during the year-ago period.The Net Loss for the quarter ended September 2025 is Rs. -7391.89 millions as compared to Net Profit of Rs. 5950.56 millions of corresponding quarter ended September 2024The company reported a degrowth in operating Profit to 1077.58 millions from 8617.03 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202509 202409 % Var 202509 202409 % Var 202503 202403 % Var
Sales 15386.60 26360.99 -41.63 39335.88 49656.36 -20.78 92264.09 78911.19 16.92
Other Income 2857.56 830.77 243.97 3550.91 1387.25 155.97 3563.66 11680.24 -69.49
PBIDT 1077.58 8617.03 -87.49 9052.52 15484.53 -41.54 26005.46 24096.87 7.92
Interest 233.96 117.95 98.36 388.54 271.44 43.14 487.33 2771.10 -82.41
PBDT -8474.32 8499.08 -199.71 -3886.28 15213.09 -125.55 23726.47 72029.08 -67.06
Depreciation 589.34 548.49 7.45 1165.73 1079.36 8.00 2186.29 2021.62 8.15
PBT -9063.66 7950.59 -214.00 -5052.01 14133.73 -135.74 21540.18 70007.46 -69.23
TAX -1671.77 2000.03 -183.59 -962.38 3645.86 -126.40 5436.68 18334.55 -70.35
Deferred Tax -970.05 615.40 -257.63 -962.38 1181.39 -181.46 2275.81 7834.63 -70.95
PAT -7391.89 5950.56 -224.22 -4089.63 10487.87 -138.99 16103.50 51672.91 -68.84
Equity 282.20 282.19 0.00 282.20 282.19 0.00 282.19 282.19 0.00
PBIDTM(%) 7.00 32.69 -78.58 23.01 31.18 -26.20 28.19 30.54 -7.70

Glenmark Pharma Share Price

2229.65 -18.25 (-0.81%)
20-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.00
Dr. Reddys Lab 1232.25
Cipla 1228.90
Zydus Lifesciences 936.35
Lupin 2328.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×